Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
03 Juin 2020 - 3:00AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex
vivo, announced today the pricing of an underwritten public
offering of 5,479,453 shares of its common stock at a public
offering price of $18.25 per share. Intellia also granted the
underwriters a 30-day option to purchase up to an additional
821,917 shares of its common stock. The gross proceeds from the
offering, before deducting underwriting discounts and commissions
and estimated offering expenses, are expected to be $100 million,
excluding any exercise of the underwriters' option to purchase
additional shares. All of the shares in the offering are to be sold
by Intellia.
Goldman Sachs & Co. LLC, Jefferies and SVB Leerink are
acting as joint book-running managers for the offering. The
offering is expected to close on or about June 5, 2020, subject to
customary closing conditions.
The shares of common stock are being offered by Intellia
pursuant to a shelf registration statement that was previously
filed with, and subsequently declared effective by, the U.S.
Securities and Exchange Commission (SEC). A preliminary prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering was filed with the SEC on June 1, 2020.
The final prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and may be
obtained, when available, from: Goldman Sachs & Co. LLC, by
mail at 200 West Street, New York, NY 10282, Attention: Prospectus
Department, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, by mail at 520
Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity
Syndicate Prospectus Department, by telephone at (877) 547-6340, or
by email at Prospectus_Department@Jefferies.com; or SVB Leerink
LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110,
Attention: Syndicate Department, by telephone at (800) 808-7525,
ext. 6218, or by email at syndicate@svbleerink.com; or by accessing
the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Intellia’s anticipated public offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, such as the
intended offering terms, are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Intellia’s most recent annual report on
Form 10-K and quarterly report on Form 10-Q filed with the SEC, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the SEC,
including those contained or incorporated by reference in the
preliminary prospectus supplement and accompanying prospectus
related to the public offering filed with the SEC. Any
forward-looking statements contained in this press release
represent Intellia’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date. Intellia explicitly disclaims any obligation to update any
forward-looking statements, except as required by law.
Intellia Contacts:
Investors: Lina Li Associate Director Investor
Relations +1 857-706-1612 lina.li@intelliatx.com
Media: Jennifer Mound Smoter Senior Vice
President External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024